No Data
No Data
MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory
Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate
MindBio Is Exploring Dual Listing on A Senior Exchange With Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3
LSD Microdosing For PMS? After Confirming Antidepressant Effects, Clinical Trials Will Assess If It Addresses Mood Issues
Lender Requests to Convert Loan to MindBio Shares
MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients With Major Depressive Disorder